Accelerating Product Development and Coordinating Regional Development Centers
First written in FY2016. 23 of 34 entries say "Restated". Latest entry: FY2026.
21 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The status of R&D activities and R&D expenses for each segment during the fiscal year were as follows. Total R&D expenses for the fiscal year were ¥5,445 million. From a comprehensive perspective, the Company is working on DX (digital transformation) across the entire electrical and electronic equipment design and manufacturing workflow and lifecycle. This includes introducing MBSE (model-based systems engineering) at the front end of electrical and electronic equipment design and manufacturing, and linking requirements definition and conceptual design with data management for detailed and manufacturing design and PLM systems, thereby improving traceability, shortening design and manufacturing lead times, making more efficient use of design assets and transferring the expertise of experienced engineers.」
R&D expenses increased to ¥5,445 million, with development progressing in multiple areas, including MBSE/PLM integration, AI-based design automation, advanced semiconductors and wire-harness automation. - FY2026-H1AdvancedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥2,598 million. There were no significant changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
While stating that there were no significant changes in R&D activities, the disclosure indicates that R&D expenses increased from the same period of the previous year and that product and technology development is continuing. - FY2025-H1AdvancedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥2,565 million. There were no significant changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
R&D expenses increased from ¥2,433.67 million in the same period of the previous year to ¥2,565.62 million. The statement that there were no significant changes in the status of R&D activities is also included. - FY2024AdvancedAnnual report
「The status of R&D activities and R&D expenses for each segment during the fiscal year were as follows. Total R&D expenses for the fiscal year were ¥4,917 million.」
R&D expenses increased to ¥4,917 million, and product development and commercialization are progressing in areas including AI automated component placement and routing, GENESYS integration, E3.infinite, the DS series and Unicode support. - FY2024-Q3AdvancedAnnual report
「Total R&D expenses for the cumulative period of the third quarter were ¥3,631 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the third quarter.」
Cumulative R&D expenses for the third quarter rose to ¥3,631 million from ¥3,363 million in the same period of the previous year. It is explained that there were no significant changes in the status of R&D activities. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative period of the second quarter were ¥2,433 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the second quarter.」
It is stated that R&D expenses for the first half were ¥2,433 million and that there were no significant changes in the status of R&D activities, reconfirming the policy of continuing R&D. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative period of the first quarter were ¥1,227 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the first quarter.」
It has been reconfirmed that cumulative R&D expenses for the first quarter were ¥1,227 million and that there were no significant changes in R&D activities. - FY2023AdvancedAnnual report
「Total research and development expenses for the fiscal year were ¥4,604 million.」
In addition to the increase in R&D expenses, development and commercialization are progressing across multiple products and technologies, including GENESYS, CR-8000, E3.infinite, the DS series and AI. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative period of the third quarter were ¥3,363 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the third quarter.」
It has been reconfirmed that cumulative R&D expenses for the third quarter were ¥3,363 million and that there were no significant changes in the status of R&D activities. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative period of the second quarter were ¥2,221 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the second quarter.」
It has been reconfirmed that cumulative R&D expenses for the second quarter were ¥2,221 million and that there were no significant changes in R&D activities. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative period of the first quarter were ¥1,115 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the first quarter.」
It has been reconfirmed that cumulative R&D expenses for the first quarter were ¥1,115 million and that there were no significant changes in R&D activities. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the nine-month period ended 31 December were ¥3,151 million. There were no material changes in the status of our group’s research and development activities during the nine-month period ended 31 December.」
It has been reconfirmed that R&D expenses were ¥3,151 million and that there were no significant changes in the status of R&D activities. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the cumulative period of the second quarter were ¥2,085 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the second quarter.」
R&D expenses for the first half were ¥2,085 million, and it is stated that there were no significant changes in the status of R&D activities. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative period of the first quarter were ¥1,074 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the first quarter.」
It has been reconfirmed that cumulative R&D expenses for the first quarter were ¥1,074 million and that there were no significant changes in R&D activities. - FY2021AdvancedAnnual report
「Total R&D expenses for the fiscal year were ¥4,174 million.」
R&D expenses increased from ¥4,041 million in the previous fiscal year to ¥4,174 million. Specific development work is also described for MBSE/MBD, AI, CR-8000, E3.infinite, DS-E3.infinite and Remote Work Assistant. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative period of the third quarter were ¥3,089 million. There were no significant changes in the status of the Group's R&D activities during the cumulative period of the third quarter.」
It has been reconfirmed that cumulative R&D expenses for the third quarter were ¥3,089 million and that there were no significant changes in the status of R&D activities. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the first six months of the current consolidated fiscal year were ¥2.046 billion. There were no material changes in the status of the Group's R&D activities during the first six months of the current consolidated fiscal year.」
It has been reconfirmed that cumulative R&D expenses for the second quarter were ¥2,046 million and that there were no significant changes in R&D activities. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated fiscal year were ¥1.056 billion. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
R&D expenses of ¥1.056 billion for the first quarter and the absence of material changes in R&D activities are reconfirmed. - FY2020AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥4.041 billion.」
R&D expenses increased from ¥3.717 billion in the previous fiscal year to ¥4.041 billion, with specific R&D activities in areas including MBSE/MBD, AI, CR-8000, E3.series infinite and DS-E3 described. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the first nine months of the current consolidated fiscal year were ¥2.941 billion. There were no material changes in the status of the Group's R&D activities during the first nine months of the current consolidated fiscal year.」
R&D expenses of ¥2.941 billion are reported, and the absence of material changes in the status of R&D activities is reconfirmed. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the first six months of the current consolidated fiscal year were ¥1.935 billion. There were no material changes in the status of the Group's R&D activities during the first six months of the current consolidated fiscal year.」
R&D expenses of ¥1.935 billion for the first six months and the absence of material changes in the status of R&D activities are reconfirmed. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated fiscal year were ¥970 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
R&D expenses of ¥970 million and the absence of material changes in the status of R&D activities are reconfirmed. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the first nine months of the current consolidated fiscal year were ¥2.654 billion. There were no material changes in the status of the Group's R&D activities during the first nine months of the current consolidated fiscal year.」
R&D expenses of ¥2.654 billion for the first nine months and the absence of material changes in the status of R&D activities are reconfirmed. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the first six months of the current consolidated fiscal year were ¥1.745 billion. There were no material changes in the status of the Group's R&D activities during the first six months of the current consolidated fiscal year.」
R&D expenses of ¥1.745 billion and the absence of material changes in the status of R&D activities are reconfirmed. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated fiscal year were ¥868 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
R&D expenses of ¥868 million are reported, and the absence of material changes in the status of R&D activities is reconfirmed. - FY2018AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥3.458 billion.」
R&D expenses totaled ¥3.458 billion, with function development and product commercialization in multiple areas, including CR-8000 Design Force, DS-2, DS-E3, eCADSTAR, functional safety and factory network-related products, described. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the first nine months of the current consolidated fiscal year were ¥2.591 billion. There were no material changes in the status of the Group's R&D activities during the first nine months of the current consolidated fiscal year.」
R&D expenses of ¥2.591 billion for the first nine months and the absence of material changes in the status of R&D activities are stated. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the first six months of the current consolidated fiscal year were ¥1.697 billion. There were no material changes in the status of the Group's R&D activities during the first six months of the current consolidated fiscal year.」
R&D expenses of ¥1.697 billion for the first six months and the absence of material changes in the status of R&D activities are stated. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated fiscal year were ¥834 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
R&D expenses of ¥834 million for the first quarter and the absence of material changes in R&D activities are stated. - FY2017AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥3.43 billion.」
R&D expenses totaled ¥3.43 billion, with development of specific functions and products such as CR-8000, Architecture Planner and DS-2, as well as coordination among the Japan, European and US sites, under way. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the first nine months of the current consolidated fiscal year were ¥2.615 billion. There were no material changes in the status of the Group's R&D activities during the first nine months of the current consolidated fiscal year.」
R&D expenses of ¥2.615 billion are reported, and the absence of material changes in the status of R&D activities is reconfirmed. - FY2017-Q2RestatedAnnual report
「Total R&D expenses for the first six months of the current consolidated fiscal year were ¥1.76 billion. There were no material changes in the status of the Group's R&D activities during the first six months of the current consolidated fiscal year.」
R&D expenses of ¥1.76 billion are reported, and the absence of material changes in R&D activities is reconfirmed. - FY2017-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated fiscal year were ¥900 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
Quarterly R&D expenses of ¥900 million are reported, and it is explained that there were no material changes in R&D activities. - FY2016First statedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥3.367 billion.」
R&D activities, including expanded product functionality, next-generation product development and coordination among the Japan, European and US sites, can be confirmed for the first time together with the associated amount.